सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation(Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/24/000068 Dated 25-02-2025

To,

M/s Reliance Life Sciences Pvt Ltd ,
Dhirubhai Ambani Life Sciences Center,
R-282 TTC Area of MIDC, Thane -Belapur Road,
Rabale Navi Mumbai (India) - 400701.

Subject: Application for grant of permission to conduct Phase III clinical trial titled – "A prospective,multi-center,randomized,double-blind,two-arm,parallel group, active control, comparative phase III clinical study to evaluate efficacy,safety, pharmacodynamics and immunogenicityofR-TPR-055(Tocilizumab) with RoActemra®/Actemra® in patients with moderately to severely active rheumatoid arthritis on a stable dose of methotrexate Protocol No.:RLS/IMM/2024/01; Version2.0, Dated:30Sep2024– regarding

Ref.: Your Application No BIO/CT04/FF/2024/43671 dated 25-06-2024

Sir,

With reference to your Application No. BIO/CT04/FF/2024/43671 dated 25-06-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;

(II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;

(IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;

(X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;

(XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

(XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(XVII) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified.

(XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

(XIX) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of two years from the date of its issue, unless extended by the Central Licencing Authority.

(XX) The firm should submit Clinical study report (CSR) to this office after completion of trial.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f087734 80400a43ee361b, postalCode=110002, st=Delhi, serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa12a1a126e a94fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2025.02.25 17:38:00 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

File. No. BIO/CT/24/000068

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits **M/s Reliance Life Sciences Pvt Ltd , Dhirubhai Ambani Life Sciences Center, R-282 TTC Area Of MIDC, Thane -Belapur Road,Rabale Navi Mumbai (India) – 400701** to conduct clinical trial of the new drug or investigational new drug study titled “A prospective,multi-center,randomized,double-blind,two-arm,parallel group, active control, comparative phase III clinical study to evaluate efficacy,safety, pharmacodynamics and immunogenicity of R-TPR-055(Tocilizumab) with RoActemra®/Actemra® in patients with moderately to severely active rheumatoid arthritis on a stable dose of methotrexate Protocol No.:RLS/IMM/2024/01; Version 2.0, Dated:30Sep2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 25.02.2025

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f08773480400a43ee361b, postalCode=110002, st=Delhi, serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa12a1a126ea94fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2025.02.25 17:29:01 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

CDSCO CDSCO MINISTRY OF HEALTH, GOVERNMENT OF INDIA सत्यमेव जयते

Annexure:

Details of new drug or investigational new drug:

<table>
<tr><td>Names of the new drug or investigational new drug</td><td>Tocilizumab 80mg(rDNA) solution for intravenous infusion 80mg/4ml vial</td></tr>
<tr><td>Therapeutic class</td><td>interleukin 6 receptor inhibitors</td></tr>
<tr><td>Dosage form:</td><td>Solution for infusion</td></tr>
<tr><td>Composition:</td><td><table><tr><th>Name of Ingredient</th><th>Quantity per vial</th></tr><tr><td>Tocilizumab (rDNA origin) IH-Active Ingredient</td><td>80mg</td></tr><tr><td>Disodium Hydrogen phosphate Dodecahydrate Ph.Eur-Buffer component</td><td>15 mM</td></tr><tr><td>Sodium dihydrogen phosphate dihydrate Ph.Eur-Buffer component</td><td>15 mM</td></tr><tr><td>Sucrose Ph.Eur-Stabilizer</td><td>200mg</td></tr><tr><td>Polysorbate 80 Ph.Eur-Surfactant</td><td>2 mg</td></tr><tr><td>Water for Injection IP/Ph.Eur/USP-Diluent</td><td>q.s to 4ml</td></tr><tr><td>pH</td><td>6-7</td></tr></table></td></tr>
<tr><td>Indications:</td><td>For the treatment of Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease Modifying Anti Rheumatic Drugs</td></tr>
</table>

Names of the new drug or investigational new drug	Tocilizumab 200mg(rDNA) solution for intravenous infusion 200mg/10ml vial
Therapeutic class	interleukin 6 receptor inhibitors
Dosage form:	Solution for infusion

<table>
<tr><td>Composition:</td><td>
<table>
<tr><th>Name of Ingredient</th><th>Quantity per vial</th></tr>
<tr><td>Tocilizumab (rDNA origin) IH-Active Ingredient</td><td>200mg</td></tr>
<tr><td>Disodium Hydrogen phosphate Dodecahydrate Ph.Eur-Buffer component</td><td>15 mM</td></tr>
<tr><td>Sodium dihydrogen phosphate dihydrate Ph.Eur-Buffer component</td><td>15 mM</td></tr>
<tr><td>Sucrose Ph.Eur-Stabilizer</td><td>500mg</td></tr>
<tr><td>Polysorbate 80 Ph.Eur-Surfactant</td><td>5 mg</td></tr>
<tr><td>Water for Injection IP/Ph.Eur/USP-Diluent</td><td>q.s to 10ml</td></tr>
<tr><td>pH</td><td>6-7</td></tr>
</table>
</td></tr>
<tr><td>Indications:</td><td>For the treatment of Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease Modifying Anti Rheumatic Drugs</td></tr>
</table>

<table>
<tr><td>Names of the new drug or investigational new drug</td><td>Tocilizumab 400mg(rDNA) solution for intravenous infusion 400mg/20ml vial</td></tr>
<tr><td>Therapeutic class</td><td>interleukin 6 receptor inhibitors</td></tr>
<tr><td>Dosage form:</td><td>Solution for infusion</td></tr>
<tr><td>Composition:</td><td>
<table>
<tr><th>Name of Ingredient</th><th>Quantity per vial</th></tr>
<tr><td>Tocilizumab (rDNA origin) IH-Active Ingredient</td><td>400mg</td></tr>
<tr><td>Disodium Hydrogen phosphate Dodecahydrate Ph.Eur-Buffer component</td><td>15 mM</td></tr>
<tr><td>Sodium dihydrogen phosphate dihydrate Ph.Eur-Buffer component</td><td>15 mM</td></tr>
<tr><td>Sucrose Ph.Eur-Stabilizer</td><td>1gm</td></tr>
<tr><td>Polysorbate 80 Ph.Eur-Surfactant</td><td>10 mg</td></tr>
<tr><td>Water for Injection IP/Ph.Eur/USP-Diluent</td><td>q.s to 20ml</td></tr>
<tr><td>pH</td><td>6-7</td></tr>
</table>
</td></tr>
<tr><td>Indications:</td><td>For the treatment of Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease Modifying Anti Rheumatic Drugs</td></tr>
</table>

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Dept. Of Rheumatology and Immunology, Room #26, 1st floor, Dhanwantari OPD block. SMS Hospital Jaipur-302004, India	Ethics Committee, S.M.S. Medical College and Attached Hospitals, J.L.N. Marg, Jaipur, Rajasthan – 302004 EC Reg. No. ECR/26/Inst/RJ/2013/RR-19	Dr. Aradhana Singh
2	AIIMS, MIHAN, Nagpur, Sumthana, Dahegaon, Maharashtra-441108, India	Institutional Ethics Committee for Clinical Trial, All India Institute of Medical Sciences, Nagpur, M/S Director AIIMS, Plot No 2, Sector 20, 1st floor, OPD Building, MIHAN, Nagpur, Maharashtra - 441108 EC Reg. No. ECR/1392/Inst/MH/2020	Dr. Saurabh Shah
3	AIIMS Bhubaneshwar, Sijua, Patrapada, Po-Dumduma, Odisha-751019, India	Institutional Ethics Committee, All India Institute of Medical Sciences, BBSR, AIIMS Bhubaneswar, Sijua, P/O Patrapada, Bhubaneswar, Khordha, Orissa – 751019 EC Reg. No. ECR/534/Inst/OD/2014/RR-20	Dr. Sujata Devi
4	V.S General Hospital, Madalpur Gam, Ellisbridge, Ahmedabad, Gujarat-380006, India.	Institutional Ethics Committee Aatman HospitalAatman Hospital, 5, Anveshan Row House, Opp Umiya Mata Mandir, Bopal Ghuma Main Road, Bopal Ghuma, Ahmedabad, Gujarat – 380058 EC Reg. No. ECR/1565/Inst/GJ/2021	Dr. Dhaiwat Shukla
5	Department of General Medicine, Rheumatology Unit, Medical College and Hospital, 88 College Street, Kolkata, West Bengal-700073, India	Institutional Ethics Committeee for Human Research , Medical College, Kolkata, 88, College Street, Kolkata, West Bengal - 700073 EC Reg. No. ECR/287/Inst/WB/2013/RR-19	Dr. Kaushik Basu
6	Institute of Post Graduate Medical Education & Research, 244 AJC Bose Road, Kolkata, West Bengal-700020, India	IPGME and R Research Oversight Committee, Institute of Postgraduate Medical Education & Research, 244 Acharya J. C. Bose Road, Kolkata, West Bengal - 700020 EC Reg. No. ECR/35/Inst/WB/2013/RR-19	Dr. Parasar Gosh

7	Medipoint Hospital Pvt. Ltd, 241/1, New D.P Road, Aundh, Pune, Maharashtra–411007, India	Penta-Med Ethics Committee, Medipoint Hospitals Pvt. Ltd., 241/1, New D.P. Road, Near Sai Heritage, Aundh, Pune, Maharashtra - 411007 EC Reg. No. ECR/357/Inst/MH/2013/RR-20	Dr Girish Kakade
8	Helios Bharti Hospital, Shama Arcade, 2nd and 3rd Floor, Sr.No. 111 CTS no. 7891, Kalewadi Main Rd,Near Jyotiba Mangal Karyalaya, and PCMC Bank, Kalewadi Pimpri Chinchwad Maharashtra - 411017	Saikrupa Hospital Institutional Ethics Committee, Saikrupa Hospital, Renuka Corner, Tapkir Chowk, Thergaon, Pune, Maharashtra - 411033 EC Reg. No. ECR/1350/Inst/MH/2020	Dr Pravin Patil
9	Department of Rheumatology and Immunology, Sir Ganga Ram Hospital, Sir Ganga Ram Hospital Marg, Rajinder Nagar New Delhi - 110060	Sir Ganga Ram Hospital Ethics Committee, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060 EC Reg. No. ECR/20/Inst/DL/2013/RR-19	Dr Lt General Ved Chaturvedi
10	Chennai Meenakshi Multispecialty Hospital, Old no. 149, New no. 72, Luz Church Road Mylapore Tamil Nadu - 600004	CMMHEC,Chennai Meenakshi Multispeciality Hospital Limited, Old No 148, New 72, Luz Church Road, Mylapore, Chennai, Tamil Nadu - 600004 EC Reg. No. ECR/516/INST/TN/2014/RR-20	Dr Krishnamurthy Venkataraman
11	NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Digdoh Hills, Police Nagar, Digdoh Nagpur Maharashtra - 440019	Institutional Ethics Committee MEBEH, Mahatme Eye Bank Eye Hospital, 2163-C, Chintaman Nagar, Near Rajiv Nagar, Somalwada, Nagpur, Maharashtra - 440025 EC Reg. No. ECR/638/Inst/MH/2014/RR-20	Dr Sushil Mankar
12	Shri Nidaan Hospital and Hope Fertility Centre, 27- Vidhut Nagar,A- Ajmer Road Jaipur Rajasthan - 302021	Swastic Ethics Committee, Shri Nidaan Hospital & Hope Fertility Centre, 27, Vidhut Nagar-A, Ajmer Road, Jaipur, Rajasthan - 302021 EC Reg. No. ECR/434/INST/RJ/2013/RR19	Dr Avinash Agarwal

13	Amber Clinic, 401-402, 4th Floor,Santorini Square, Behind Abhishree Complex, Near Jodhpur Cross Rd, opp. Star Bazaar Satellite Ahmedabad Gujarat - 380015	Institutional Ethics Committee Deen Dayal Upadhyay Hospital, Shaheed Mangal Pandey Marg, Nanak Pura, Hari Nagar, New Delhi- 110064 EC Reg. No. ECR/147/Inst/GJ/2013/RR-19	Dr Vishnu Sharma

CENTRAL DRUGS STANDARD CONTROL ORGANISATION
CDSCO CDSCO
सत्यमेव जयते
MINISTRY OF HEALTH, GOVERNMENT OF INDIA